Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$3.6B
96M shares
52-week range
$23.23 – $40.58
78% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
www.ideayabio.comNo one on the platform currently holds IDYA.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-03-31 | 357,600 | $5.9M |
No one on the platform has traded IDYA yet.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$IDYA Price: $36.91 (-0.13%) Trend: Bullish Market Bias (7D): Bearish Bias 📉 Expected Range: ±0.68% RSI: 61.3 | Momentum: Moderate Volume: -74.9% vs avg Volatility: 1.93% Support: $34.01 | Resistance: $37.90 Data and analytics sourced from Thescanner educational research https://www.thescanner.ai
View on StockTwits ↗$IDYA The fake algo hungergames are in full bloom here. Volume dead. This can a take a few weeks, but not forever. South or North we go and soon.
View on StockTwits ↗$IDYA •2H26: Complete NDA filing for darovasertib in uveal melanoma •2H26: Initiate combo IDE892 with RG6505 (panRAS) •2H26: Clinical update for darovasertib in HLA-A2 positive patients at ESMO •2H26: Clinical update for darovasertib in neoadjuvant primary UM (OptimUM-09 trial) at ESMO •2H26: Hengrui update for IDE849 (DLL3 ADC) at ESMO •4Q26: R&D day •2H26: IDE849 Ph1/2 US clinical update •2H26: IDE034 Ph1/2 clinical update I expect great result after great result and a stock price of 2b EV.
View on StockTwits ↗$IDYA https://www.prnewswire.com/news-releases/ideaya-biosciences-reports-second-quarter-2026-financial-results-and-provides-business-update-302841723.html
View on StockTwits ↗$IDYA Credit to @RonIsWrong https://ir.ideayabio.com/2026-07-27-IDEAYA-Biosciences-Announces-IDE892,-a-Potential-Best-in-Class-MTA-Cooperative-PRMT5-Inhibitor,-Initiates-Part-2-Monotherapy-Expansion-in-the-Phase-1-2-Study-in-MTAP-Deleted-Pancreatic-and-Lung-Cancers
View on StockTwits ↗@CH_Expat @jwon3 He may be great too, but you are one of greatest posters about $IDYA tho
View on StockTwits ↗$IDYA IDEAYA Biosciences: the darovasertib approval trade — and the pipeline the market may still be underpricing https://www.merlintrader.com/ideaya-biosciences-stock-hub/
View on StockTwits ↗$IDYA Very unusual stock price behavior since the opening bell. Just saying. Probably to myself only.
View on StockTwits ↗$IDYA Adding zone 28-30. $MLYS Adding zone 23-24 Candidates at lower prices: CLDX, TRVI, NRIX, IVA, SNDX, KURA Candidates at much lower prices: COGT, CELC Horror-All-Star-Trash-Team: ALT, SLS, TNXP, CADL, CAPR
View on StockTwits ↗$IDYA At this levels, not even all indiciations for Daro are priced in. None is 892, 849 and 034. Not to mention the others. Boreout range here before the magic begins. Yujiro leading BOD also tells me he wants clean track to sell in 2027 or 2028. If CRNX can go for 10b, IDYA can do the same.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $36M | -83.2% | $-4.25 | $-4.87–$-3.62 | — | 10 |
| 2027 | $115M | +215.7% | $-3.65 | $-4.77–$-1.36 | — | 10 |
| 2028 | $250M | +117.4% | $-2.97 | $-4.10–$0.12 | — | 11 |
| 2029 | $563M | +125.3% | $-0.98 | $-2.05–$-0.07 | — | 4 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 3 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-04 | $-1.06 | $-1.22 | -15.1% |
| 2026-05-05 | $-1.07 | $-1.11 | -3.7% |
| 2026-02-17 | $-0.95 | $-0.94 | +1.2% |
| 2025-11-04 | $-0.95 | $1.33 | +240.6% |
| 2025-08-05 | $-0.85 | $-0.88 | -3.5% |
| 2025-05-06 | $-0.75 | $-0.82 | -9.3% |
| 2025-02-13 | $-0.67 | $-1.49 | -122.4% |
| 2024-11-04 | $-0.67 |
| $-0.60 |
| +10.4% |
| -4.28% |
| $6.4B |
| — |
| FOLDAmicus Therapeutics, Inc. | $14.49 | +0.00% | $4.5B | — |
| KNSAKiniksa Pharmaceuticals International, plc | $77.83 | -0.41% | $5.9B | — |
Source: Financial Modeling Prep · peers by sector/industry